Primary nonfunction of islet grafts in autoimmune diabetic nonobese diabetic mice is prevented by treatment with interleukin-4 and interleukin- 10

Transplantation

Volumn 62, Issue 5, 1996, Pages 648-652

  Faust, Antje ^b   Rothe, Helga ^b   Schade, Ulrich ^b   Lampeter, Eberhard ^b   Kolb, Hubert ^a,b  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; MESSENGER RNA; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 4; STREPTOZOCIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MECHANISM; DRUG MIXTURE; FEMALE; GRAFT FAILURE; GRAFT REJECTION; HELPER CELL; HYPERGLYCEMIA; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL;

EID: 0029810079     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199609150-00019     Document Type: Article

References (36)

1. Kikutani H, Makino S. The murine autoimmune diabetes model: NOD and related strains. Adv Immunol 1992; 51: 285.
2. Rossini AA, Greiner DL, Friedman HP, Mordes JP. Immunopathogenesis of diabetes mellitus. Diabetes Rev 1993; 1: 43.
3. Serreze DV, Leiter EH. Genetic and pathogenic basis of autoimmune diabetes in NOD mice. Curr Opin Immunol 1994; 6: 900.
4. Bowman MA, Leiter EH, Atkinson MA. Prevention of diabetes in the NOD mouse: implications for therapeutic intervention in human disease. Immunol Today 1994; 15: 115.
5. Mellgren A, Schnell AH, Petersson B, Andersson A. The renal subcapsular site offers better growth conditions for transplanted mouse pancreatic islet cells than liver or spleen. Diabetologia 1986; 29: 670.
6. Wang T, Singh B, Warnock GL, Rajotte RV. Prevention of recurrence of IDDM in islet-transplanted diabetic NOD mice by adjuvant immunotherapy. Diabetes 1992; 41: 114.
7. Wang Y, McDuffie M, Nomikos IN, Hao L, Lafferty KJ. Effect of cyclosporine on immunologically mediated diabetes in nonobese diabetic mice. Transplantation 1988; 46 (suppl): 101S.
8. 8 T cells in the destruction of islet grafts by spontaneously diabetic mice. Proc Natl Acad Sci USA 1991; 88: 527.
9. + T lymphocytes in primary nonfunction and classical rejection on islet allografts. J Exp Med 1990; 172: 291.
10. Anderson JT, Cornelius JG, Jarpe AJ, Winter PE, Peck AB. Insulin-dependent diabetes in the NOD mouse model. II. β cell destruction in autoimmune diabetes is a TH2 and not a TH1 mediated event. Autoimmunity 1993; 15: 113.
11. Rothe H, Faust A, Schade U, et al. Cyclophosphamide treatment of female non-obese diabetic mice causes enhanced expression of inducible nitric oxide synthase and interferon-gamma, but not of interleukin-4. Diabetologia 1994; 37: 1154.
12. Shehadeh NN, LaRosa F, Lafferty KJ. Altered cytokine activity in adjuvant inhibition of autoimmune diabetes. J Autoimmunity 1993; 6: 291.
13. Rabinovitch A, Sorensen O, Suarez-Pinzon WL, Power RF, Rajotte RV, Bleakley RC. Analysis of cytokine mRNA expression in syngeneic islet grafts of NOD mice: interleukin 2 and interferon gamma mRNA expression correlate with graft rejection and interleukin 10 with graft survival. Diabetologia 1994; 37: 833.
14. Rapoport MJ, Jaramillo A, Zipris D, et al. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 1993; 178: 87.
15. Harada M, Makino S. Promotion of spontaneous diabetes in non-obese diabetes-prone mice by Cyclophosphamide. Diabetologia 1984; 27: 604.
16. Charlton B, Bacelj A, Mandel TE. Administration of silica particles or anti-Lyt2 antibody prevents ß-cell destruction in NOD mice given cyclophosphamide, Diabetes 1988; 37: 930.
17. Lee K-U, Amano K, Yoon J-W. Evidence for initial involvement of macrophage in development of insulitis in NOD mice. Diabetes 1988; 37: 989.
18. Appels B, Burkart V, Kantwerk-Funke G, Kolb-Bachofen V, Kolb H. Spontaneous cytotoxicity of macrophages against pancreatic islet cells. J Immunol 1989; 142: 3803.
19. Faust A, Burkart V, Ulrich H, Weischer CH, Kolb H. Effect of lipoic acid on cyclophosphamide-induced diabetes and insulitis in non-obese diabetic mice. Int J Immunopharmacol 1994; 16: 61.
20. Charlton B, Bacelj A, Slattery RM, Mandel TE. Cyclophosphamide-induced diabetes in NOD/Wehi mice: evidence for suppression in spontaneous autoimmune diabetes mellitus. Diabetes 1989; 37: 441.
21. Sutherland DER, Goetz FC, Najarian JS. Pancreas transplants from related donors. Transplantation 1984; 38: 625.
22. Marquet RL, Bonthuis F, Duval SY, et al. Macrophages and nitric oxide are involved in primary nonfunction of islet xenografts. Transplant Proc 1995; 27: 252.
23. Szczepanik M, Bryniarsky K, Pryjma J, Ptak W. Distinct populations of antigen-presenting macrophages are required for induction of effector and regulatory cells in contact sensitivity response in mice. J Leukocyte Biol 1993; 53: 320.
24. Kasuga A, Maruyama T, Takei I, et al. The role of cytotoxic macrophages in non-obese diabetic mice: cytotoxicity against murine mastocytoma and beta-cell lines. Diabetologia 1993; 36: 1252.
25. Rothe H, Burkart V, Faust A, Kolb H. Interleukin-12 gene expression is associated with rapid development of diabetes mellitus in non-obese diabetic mice. Diabetologia 1996; 39: 119.
26. Vaunier E, Miller LC, Dinarello CA. Coordinated antiinflammatory effects of interleukin 4: interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist. Proc Natl Acad Sci USA 1992; 89: 4076.
27. Allen JB, Wong HL, Costa GL, Bienkowsky MJ, Wahl SM. Suppression of monocyte function and differential regulation of IL-1 and IL-1ra by IL-4 contribute to resolution of experimental arthritis. J Immunol 1993; 151: 4344.
28. Mulligan MS, Jones ML, Vaporciyan AA, Howard MC, Ward PA. Protective effects of IL-4 and IL-10 against immune complexinduced lung injury. J Immunol 1993; 151: 5666.
29. Cenci E, Romani L, Mencacci A, et al. Interleukin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of Candida albicans. Eur J Immunol 1993; 23: 1034.
30. Bogdan C, Vodovotz Y, Nathan C. Macrophage deactivation by interleukin 10. J Exp Med 1991; 174: 1549.
31. Rott O, Fleischer B, Cash E. Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur J Immunol 1994; 24: 1434.
32. Gérard C, Bruyns C, Marchant A, et al. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoximia. J Exp Med 1993; 177: 547.
33. Fiorentino DF, Zlotnik A, Vieira P, et al. II-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146: 3444.
34. Powrie F, Menon S, Coffman RL. Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vivo. Eur J Immunol 1993; 23: 3043.
35. Chao S-H, Chu SH, Lee S-C, Lin J-K, Chen K-M. Interleukin-10 (IL-10) prevents primary nonfunction in allogeneic islet transplantation. Transplant Proc 1995; 27: 602.
36. Rabinovitch A, Suarez-Pinzon WL, Sorensen O, Bleackley C, Power RF, Rajotte RV. Combined therapy with interleukin-4 and interleukin-10 inhibits autoimmune diabetes recurrence in syngenic islet-transplanted nonobese diabetic mice. Transplantation 1995; 60: 368.